<DOC>
	<DOCNO>NCT01728623</DOCNO>
	<brief_summary>This study evaluate safety , efficacy , pharmacokinetics E7080 orally administer daily ( QD ) subject advanced thyroid cancer .</brief_summary>
	<brief_title>A Study E7080 Subjects With Advanced Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Inclusion criterion 1 . Histologically clinically diagnose thyroid cancer 2 . Eastern Cooperative Oncology Group Performance Status ( ECOGPS ) 02 3 . Adequate laboratory values/organ function test Exclusion criterion Subjects follow complication disease history 1 . Brain metastasis 2 . Systemic severe infection 3 . Significant cardiovascular impairment 4 . QTc great 480 millisecond 5 . Active hemoptysis 6 . Bleeding thrombotic disorder 7 . Having great 1+ proteinuria urine dipstick test undergo 24 hr urine collection quantitative assessment proteinuria 8 . Gastrointestinal malabsorption condition opinion investigator might affect absorption E7080 9 . Major surgery within 3 week enrollment 10 . With coexist effusion require drainage</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Thyroid cancer</keyword>
</DOC>